Christine M. Tarby
Bristol-Myers Squibb
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Christine M. Tarby.
Bioorganic & Medicinal Chemistry Letters | 2010
David K. Williams; Xiao-Tao Chen; Christine M. Tarby; Robert F. Kaltenbach; Zhen-Wei Cai; John S. Tokarski; Yongmi An; John S. Sack; Barri Wautlet; Johnni Gullo-Brown; Benjamin Henley; Robert Jeyaseelan; Kristen A. Kellar; Veeraswamy Manne; George L. Trainor; Louis J. Lombardo; Joseph Fargnoli; Robert M. Borzilleri
Biarylamine-based inhibitors of Met kinase have been identified. Lead compounds demonstrate nanomolar potency in Met kinase biochemical assays and significant activity in the Met-driven GTL-16 human gastric carcinoma cell line. X-ray crystallography revealed that these compounds adopt a bioactive conformation, in the kinase domain, consistent with that previously seen with 2-pyridone-based Met kinase inhibitors. Compound 9b demonstrated potent in vivo antitumor activity in the GTL-16 human tumor xenograft model.
Bioorganic & Medicinal Chemistry Letters | 2012
Liqi He; Steven P. Seitz; George L. Trainor; David R. Tortolani; Wayne Vaccaro; Michael A. Poss; Christine M. Tarby; John S. Tokarski; Becky Penhallow; Chen-Yi Hung; Ricardo M. Attar; Tai-An Lin
A series of aminothiazoles that are potent inhibitors of LIM kinases 1 and 2 is described. Appropriate choice of substituents led to molecules with good selectivity for either enzyme. An advanced member of the series was shown to effectively interfere with the phosphorylation of the LIM kinases substrate cofilin. Consistent with the important role of the LIM kinases in regulating cytoskeletal structure, treated cells displayed dramatically reduced F-actin content.
Analytical Biochemistry | 2009
Patricia A. McDonnell; Joseph Yanchunas; John A. Newitt; Li Tao; Susan E. Kiefer; Marie Ortega; S. A. Kut; Neil T. Burford; Valentina Goldfarb; Gerald J. Duke; Henry Shen; William J. Metzler; Michael L. Doyle; Zhong Chen; Christine M. Tarby; Robert M. Borzilleri; Wayne Vaccaro; Marco M. Gottardis; Songfeng Lu; Donald Crews; Kyoung S. Kim; Louis J. Lombardo; Deborah L. Roussell
Eg5 is a kinesin whose inhibition leads to cycle arrest during mitosis, making it a potential therapeutic target in cancers. Circular dichroism and isothermal titration calorimetry of our pyrrolotriazine-4-one series of inhibitors with Eg5 motor domain revealed enhanced binding in the presence of adenosine 5-diphosphate (ADP). Using this information, we studied the interaction of this series with ADP-Eg5 complexes using a thermal shift assay. We measured up to a 7 degrees C increase in the thermal melting (T(m)) of Eg5 for an inhibitor that produced IC(50) values of 60 and 130 nM in microtubule-dependent adenosine triphosphatase (ATPase) and cell-based cytotoxicity assays, respectively. In general, the inhibitor potency of the pyrrolotriazine-4-one series in in vitro biological assays correlated with the magnitude of the thermal stability enhancement of ADP-Eg5. The thermal shift assay also confirmed direct binding of Eg5 inhibitors identified in a high-throughput screen and demonstrated that the thermal shift assay is applicable to a range of chemotypes and can be useful in evaluating both potent (nM) and relatively weakly binding (microM) leads. Overall, the thermal shift assay was found to be an excellent biophysical method for evaluating direct binding of a large number of compounds to Eg5, and it complemented the catalytic assay screens by providing an alternative determination of inhibitor potency.
Cancer Research | 2015
Brent A. Rupnow; Chiang Yu; Jonathan G. Pabalan; Urvashi V. Roongta; Jonathan Lippy; Ashok Dongre; Mary T. Obermeier; Aberra Fura; Paul A. Elzinga; Benjamin Henley; Joseph Fargnoli; Francis Y. Lee; William R. Foster; Christine M. Tarby; Brian E. Fink; John S. Tokarski; Ashvinikumar V. Gavai; Tai W. Wong; John T. Hunt; Gregory D. Vite; Ashok V. Purandare
The CK2 protein kinases are a small family of two highly related serine/threonine kinases composed of two catalytic subunits, α and α’, and a single β subunit. Numerous substrates have been reported for CK2 and these proteins are known to participate in diverse cellular processes, including cell signaling, transcription, DNA repair, apoptosis regulation and tumor suppression. Elevated CK2 expression and kinase activity has been observed in many cancer types. Further, mRNA knockdown and enzyme inhibition studies have demonstrated that many cancer cell lines are dependent on CK2 for growth and survival. To further evaluate CK2 kinases as targets for therapeutic intervention in cancer, we identified BMS-595, a potent and selective, ATP-competitive CK2 inhibitor. BMS-595 inhibits the in vitro proliferation of human colorectal and lung cancer cell lines with IC50s ranging from less than 10 nM to greater than 1 μM. In sensitive cell lines, anti-proliferative effects of BMS-595 and structurally related analogs strongly correlated with cellular CK2 kinase inhibition. Oral administration of BMS-595 to mice bearing colorectal cancer and lung cancer xenografts demonstrated pharmacodynamic effects and robust efficacy at tolerated doses. These studies confirm the dependence of a subset of human colon and lung cancer cell lines on CK2 activity for growth and demonstrate that pharmacologic inhibition of CK2 can produce anti-tumor efficacy at tolerated doses. Citation Format: Brent A. Rupnow, Chiang Yu, Jonathan G. Pabalan, Urvashi V. Roongta, Jonathan S. Lippy, Ashok R. Dongre, Mary T. Obermeier, Aberra Fura, Paul A. Elzinga, Benjamin J. Henley, Joseph Fargnoli, Francis Y. Lee, William R. Foster, Christine M. Tarby, Brian E. Fink, John S. Tokarski, Ashvinikumar V. Gavai, Tai W. Wong, John T. Hunt, Gregory D. Vite, Ashok V. Purandare. Anti-tumor activity of BMS-595, a novel CK2 kinase inhibitor. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5395. doi:10.1158/1538-7445.AM2015-5395
Cancer Research | 2015
Christine M. Tarby; Liqi He; Brian E. Fink; Andrew Nation; Yufen Zhao; Soong-Hoon Kim; Libing Chen; John S. Tokarski; Chiang Yu; Jonathan G. Pabalan; Urvashi V. Roongta; Jonathan Lippy; Mary T. Obermeier; Paul A. Elzinga; Aberra Fura; Benjamin Henley; Joseph Fargnoli; William R. Foster; Ashvinikumar V. Gavai; Tai W. Wong; John T. Hunt; Gregory D. Vite; Ashok V. Purandare; Brent A. Rupnow
CK2 is a highly conserved, and constitutively active family of serine/threonine kinases abnormally elevated in a wide variety of cancers and linked to poor prognosis and disease progression. The enzymes form as hetero-tetrameric complexes comprised of two highly related catalytic subunits (α or α´) with two regulatory β subunits in various combinations and distributions, depending on cell type. While CK2 plays a role in normal growth and development, deregulation of the enzymes has been shown to promote and maintain a malignant phenotype through mechanisms in both the anti-apoptotic and the pro-proliferative signaling pathways. CK2 has been reported to modulate the activity of several oncogenic transcription factors including CREB, Myc, Jun and Fos. Studies with RNAi and small molecule compounds have demonstrated tumor cell dependence on CK2. We sought to identify potent CK2 inhibitors to probe the function of CK2 in cancer-linked pathways and for evaluation in CK2 dependent tumor xenograft models. Herein we report SAR studies in the imidazo[1,2-b]pyridazine chemotype leading to the discovery of BMS-595, a highly potent and selective ATP-competitive CK2 inhibitor with a commensurate level of cellular potency. BMS-595 demonstrates strong PK/PD correlations and robust, oral anti-tumor efficacy in CK2-driven xenograft models at tolerated doses. Citation Format: Christine M. Tarby, Liqi He, Brian E. Fink, Andrew Nation, Yufen Zhao, Soong-Hoon Kim, Libing Chen, John S. Tokarski, Chiang Yu, Jonathan G. Pabalan, Urvashi V. Roongta, Jonathan Lippy, Mary Obermeier, Paul A. Elzinga, Aberra Fura, Benjamin Henley, Joseph J. Fargnoli, William R. Foster, Ashvinikumar V. Gavai, Tai W. Wong, John T. Hunt, Gregory D. Vite, Ashok V. Purandare, Brent A. Rupnow. The identification of BMS-595, an orally active imidazo[1,2-b]pyridazine CK2 inhibitor with in vivo anti-tumor activity. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5417. doi:10.1158/1538-7445.AM2015-5417
Bioorganic & Medicinal Chemistry Letters | 2006
Christine M. Tarby; Robert F. Kaltenbach; Tram Huynh; Andrew T. Pudzianowski; Henry Shen; Marie Ortega-Nanos; Steven Sheriff; John A. Newitt; Patricia A. McDonnell; Neil T. Burford; Craig R. Fairchild; Wayne Vaccaro; Zhong Chen; Robert M. Borzilleri; Joseph G. Naglich; Louis J. Lombardo; Marco M. Gottardis; George L. Trainor; Deborah L. Roussell
Archive | 2000
Christine M. Tarby; Wilna Moree
Archive | 2013
Ashok V. Purandare; Brian E. Fink; Walter Lewis Johnson; Amy C. Hart; Liqi He; Tram N. Huynh; Jennifer Inghrim; Harold Mastalerz; Xiaopeng Sang; Christine M. Tarby; Honghe Wan; Wayne Vaccaro; Guifen Zhang; Yufen Zhao; Kurt Zimmermann; Yong Zhang; Libing Chen; Bin Chen; John S. Tokarski; Ashvinikumar V. Gavai
Archive | 2017
Amy C. Hart; Ashok V. Purandare; Ashvinikumar V. Gavai; Bin Chen; Brian E. Fink; Christine M. Tarby; Guifen Zhang; Harold Mastalerz; Honghe Wan; Jennifer Inghrim; John S. Tokarski; Kurt Zimmermann; Libing Chen; Liqi He; Tram N. Huynh; Walter Lewis Johnson; Wayne Vaccaro; Xiaopeng Sang; Yong Zhang; Yufen Zhao
Archive | 2000
Barry L. Johnson; Mona Patel; James David Rodgers; Haisheng Wang; Christine M. Tarby; Rajagopal Bakthavatchalam